GENOMIC EXPRESSION ApS is a Danish APS based in København NV, operating in the Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik sector. Incorporated in 2000, the company has 1 employee and reported a gross profit of -DKK 89.0k in its latest annual filing.
| Gross profit | -0.1M DKK | +710% |
| EBITDA | -0.3M DKK | -2373% |
| Net profit | -0.4M DKK | -147% |
| Total assets | 0.4M DKK | -57% |
| Equity | -1.1M DKK | -70% |
| Employees | 1 | — |
In its most recent annual report (2022), GENOMIC EXPRESSION ApS reported a gross profit of -DKK 89.0k. The figures on this page draw on 5 annual filings covering 2018 to 2022. The bottom line showed a net loss of DKK 434.6k.
At the end of 2022, current assets covered short-term debt 0 times.
| Item | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Gross profit | -89 | -11 | -250 | -418 | 794 |
| Staff expenses | -0 | -0 | -307 | -134 | -652 |
| EBITDA | -275 | -11 | -557 | -552 | 142 |
| Depreciation & amort. | -158 | -158 | -158 | -158 | -158 |
| EBIT | -433 | -169 | -715 | -710 | -17 |
| Net financials | -2 | -7 | 77 | 899 | -930 |
| Profit before tax | -435 | -176 | -638 | 189 | -947 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | -435 | -176 | -638 | 189 | -947 |
| Item | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Total assets | 414 | 972 | 1,154 | 2,765 | 8,935 |
| Equity | -1,059 | -624 | -448 | 190 | 1 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1,473 | 1,596 | 1,602 | 2,575 | 8,934 |
| Total debt | 1,473 | 1,596 | 1,602 | 2,575 | 8,934 |
28 financial ratios from the latest filing, each graded against companies in the same industry.
Net profit as a percentage of total assets — the return generated on the capital employed.
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA relative to debt — how much operating earnings are available to service the debt.
The ability to pay the interest on the company's debt out of its earnings.
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
The size of this year's increase or decrease in the company's debt.
Revenue relative to total assets — the ability to generate revenue from the asset base.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
The size of this year's increase or decrease in the company's equity.
| Name | Role | Member since |
|---|
ML Management | Management | 2000 – 2002 |
JZ Chief Executive Officer | Chief Executive Officer | 2011 – 2021 |
GL Management | Management | 2002 – 2023 |
| Name | Role | Member since |
|---|
MC Board of Directors | Board of Directors | 2006 – 2009 |
AK Board of Directors | Board of Directors | 2000 – 2003 |
ML Board of Directors | Board of Directors | 2011 – 2023 |
GL Chairman | Chairman | 2000 – 2023 |
| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
Uptown Developments Ltd. | Company | 5–9.99% | 5–9.99% | 2013 |
| Company | 33.33–49.99% | 33.33–49.99% | 2013 | |
Genomic Expression Inc | Company | 50–66.65% | 50–66.65% | 2013 |
| Person | Role here | Other companies |
|---|---|---|
| Anne Katrine Winterø | Board of Directors | 4 companies |
| Morten Lorentz Pedersen | Management | 3 companies |
| Gitte Laurette Pedersen | Management | 2 companies |
| Mark Csaba Szigethy | Board of Directors | 1 company |